// App-Quantinova.ai

5570 : Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician’s choice (TPC).

Researchers

Presenter

  • Nicoletta Colombo

Principal Investigators

  • Alessandro Santin

  • Emeline Colomba

  • David Scott Miller

  • Keiichi Fujiwara

  • Sandro Pignata

  • Sally E. Baron-Hay

  • Isabelle Laure Ray-Coquard

  • Ronnie Shapira-Frommer

  • Yong Man Kim

  • Mary McCormack

  • Steven Bird

  • Vimalanand S. Prabhu

  • Allison Martin Nguyen

  • Qi Zhao

  • Lea Dutta

  • Vicky Makker

  • Domenica Lorusso

Medical Centers

  • University of Milano-Bicocca and European Institute of Oncology, Milano, Italy

  • San Carlos University Teaching Hospital, Madrid, Spain

  • Smilow Comprehensive Cancer Center, Yale School of Medicine, New Haven, CT, Gustave Roussy Cancerology Institute, Villejuif, Gineco Group, France

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • Saitama Medical University International Medical Center, Hidaka, Japan

  • Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

  • Royal North Shore Hospital, St Leonards, Australia

  • GINECO, Centre Leon Berard and University Claude Bernard, Lyon, France

  • Sheba Medical Center, Ramat-Gan, Ireland

  • Asan Medical Center, University of Ulsan, Seoul, South Korea

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Merck & Co., Inc., Kenilworth, NJ, Eisai Inc., Woodcliff Lake, NJ, Memorial Sloan Kettering Cancer Center, New York, NY, Gynecologic Oncology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS and Scientific Directorate, Rome, Italy

Locations

  • Italy

  • Spain

  • France

  • Japan

  • Australia

  • Israel

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Endometrial Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Doxorubicin

  • Lenvatinib

  • Paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • NCT03517449

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved